Company news

Vir Biotechnology, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Vir Biotechnology to Host a Virtual Hepatitis Portfolio R&D Day

April 12, 2022

Vir Biotechnology Scientists Named Winners of the BARDA and HHS-Sponsored Pediatric COVID-19 Data Challenge

April 5, 2022

Vir Biotechnology to Participate in the 21st Annual Needham Healthcare Conference

April 3, 2022

Vir Biotechnology to Participate in the 42nd Annual Cowen Healthcare Conference

March 1, 2022

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

February 23, 2022

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022

February 9, 2022

Data Suggest Sotrovimab Retains Neutralizing Activity Against Omicron Subvariant BA.2

February 8, 2022

Vir Biotechnology Appoints Johanna Friedl-Naderer as Executive Vice President and Chief Business Officer, Global

February 7, 2022

Vir Biotechnology Launches New Antibody Research Initiative Aimed at a Functional Cure for HIV and Prevention of Malaria

January 12, 2022

GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration of Sotrovimab for the Early Treatment of COVID-19

January 12, 2022

GSK and Vir Biotechnology Announce United States Government Agreement to Purchase Additional Supply of Sotrovimab, Authorized for the Early Treatment of COVID-19

January 10, 2022

Vir Biotechnology to Present at 40th Annual J.P. Morgan Healthcare Conference

January 3, 2022

Vir Biotechnology Announces New Research Describing the Structural Basis of SARS-CoV-2 Omicron Immune Evasion and Receptor Engagement

December 30, 2021

Xevudy (Sotrovimab) Granted Marketing Authorization by the European Commission for the Early Treatment of COVID-19

December 16, 2021

Vir Biotechnology Announces Initiation of Phase 2 Clinical Trial Evaluating VIR-2218, Selgantolimod and Nivolumab for the Treatment of Chronic Hepatitis B Virus Infection

December 8, 2021

Vir Biotechnology to Host a Call on Sotrovimab’s Retained Activity Against the Omicron SARS-CoV-2 Variant

December 6, 2021

Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron SARS-CoV-2 Variant

December 6, 2021

Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant

December 1, 2021

GSK and Vir Biotechnology Announce United States Government Agreements to Purchase Sotrovimab, a COVID-19 Treatment

November 16, 2021

Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection at AASLD The Liver Meeting®

November 11, 2021

Primary endpoint met in COMET-TAIL Phase 3 trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19

November 11, 2021

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2021 Financial Results

November 3, 2021

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2021 Financial Results on November 4, 2021

October 20, 2021

Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2021

October 14, 2021

Vir Biotechnology to Participate in the H. C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference

October 5, 2021

Vir Biotechnology to Participate in the Guggenheim 2nd Annual Vaccine & Infectious Disease Day Conference

September 29, 2021

Vir Biotechnology to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

September 7, 2021

Vir Biotechnology to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

September 6, 2021

Vir Biotechnology Announces First Marketing Authorization for its First Commercial Product, Sotrovimab, Granted in Australia

August 22, 2021

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2021 Financial Results

August 4, 2021

GSK and Vir Biotechnology Announce Joint Procurement Agreement with European Commission for COVID-19 Treatment, Sotrovimab

July 27, 2021

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2021 Financial Results on August 5, 2021

July 21, 2021

Vir Biotechnology Initiates Phase 2 Clinical Trial Evaluating the Combination of VIR-2218 and VIR-3434 as a Functional Cure Regimen for Chronic Hepatitis B Virus Infection

July 14, 2021

Vir Biotechnology Presents New Clinical Data from Ongoing Trials of VIR-2218 and VIR-3434 in Patients with Chronic Hepatitis B Virus Infection at the International Liver Congress 2021

June 24, 2021

GSK and Vir Biotechnology Announce Continuing Progress of the COMET Clinical Development Program for Sotrovimab

June 20, 2021

Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Oral and Poster Presentations at EASL 2021

June 13, 2021

Vir Biotechnology to Participate in the Goldman Sachs 42nd Annual Global Healthcare Conference

June 1, 2021

GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from the US FDA for Treatment of Mild-to-Moderate COVID-19 in High-Risk Adults and Pediatric Patients

May 25, 2021

EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology’s Sotrovimab For the Early Treatment of COVID-19

May 20, 2021

Vir Biotechnology Reminds Stockholders of 2021 Annual General Meeting Details

May 9, 2021

GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831 (sotrovimab) for the Early Treatment of COVID-19

May 6, 2021

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2021 Financial Results

May 5, 2021

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2021 Financial Results on May 6, 2021

April 21, 2021

Brii Biosciences, Vir Biotechnology and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B

April 20, 2021

Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B

April 20, 2021

GSK and Vir Biotechnology Announce EMA Review of Dual-Action Monoclonal Antibody VIR-7831 for the Early Treatment of COVID-19

April 14, 2021

Vir Biotechnology Announces New Research Demonstrating Novel Mechanisms by Which SARS-CoV-2 Enters Host Cells

April 7, 2021

Vir Biotechnology to Present at the 20th Annual Needham Virtual Healthcare Conference

April 5, 2021

Vir Biotechnology Announces New Preclinical Research Demonstrating VIR-7831 Maintains Neutralizing Activity Against the SARS-CoV-2 California Variant

April 4, 2021

Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19

March 28, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 14 calls. Every call is listed under its year.

Decks

The 5 newest of 30 decks. Every deck is listed under its year.